Atreca, Inc. (BCEL) Stock Analysis

Atreca, Inc. (BCEL) Healthcare & Pipeline Overview

Atreca, Inc. is a clinical-stage biotechnology company specializing in antibody-based immunotherapeutics for solid tumors, leveraging its proprietary discovery platform to develop novel treatments like ATRC-101, targeting unmet needs in ovarian, lung, colorectal, and breast cancers, and collaborating with Xencor and the Bill & Melinda Gates Medical Research Institute.

What Is the Investment Thesis for BCEL?

Atreca, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful clinical development and commercialization of its lead product candidate, ATRC-101, and other pipeline assets. A key value driver is the potential efficacy of ATRC-101 across multiple solid tumor types, as suggested by its in vitro reactivity with a majority of ovarian, lung, colorectal, and breast cancer samples. Upcoming clinical trial results for ATRC-101 will be a critical catalyst. Further growth may be driven by the advancement of APN-122597 and ATRC-501/MAM01. However, the company's negative profit margin of -12617.8% and gross margin of -819.6% highlight the significant financial risks associated with drug development. The company's success is also dependent on its ability to maintain and expand its collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute.

Based on FMP financials and quantitative analysis

BCEL Key Highlights

Atreca, Inc. is a clinical-stage biopharmaceutical company focused on antibody-based immunotherapeutics.

• Lead product candidate ATRC-101 targets a novel mechanism of action and reacts with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples in vitro.
• Developing APN-122597, a receptor tyrosine kinase inhibitor targeting tumor tissues.
• Developing ATRC-501/MAM01 for the prevention of malaria, in collaboration with the Bill & Melinda Gates Medical Research Institute.
• Profit margin is -12617.8% and gross margin is -819.6%.

Who Are BCEL's Competitors?

BCEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BCEL's Key Strengths?

Proprietary antibody discovery platform.

• Novel mechanism of action of ATRC-101.
• Strategic collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute.
• Focus on unmet needs in solid tumor treatment.

What Are BCEL's Weaknesses?

Clinical-stage company with no currently approved products.

• High reliance on the success of ATRC-101.
• Negative profit and gross margins.
• Limited financial resources compared to larger pharmaceutical companies.

What Could Drive BCEL Stock Higher?

Clinical trial data readouts for ATRC-101 in various solid tumor types.

• Potential regulatory milestones for ATRC-101, including breakthrough therapy designation.
• Advancement of APN-122597 and ATRC-501/MAM01 through preclinical and clinical development.
• Expansion of strategic partnerships and collaborations.

What Are the Key Risks for BCEL?

Financial-distress signal — its Altman Z-Score of -37.57 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-83.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for ATRC-101 and other pipeline candidates.
• Regulatory hurdles and approval delays.
• Competition from established pharmaceutical companies with greater resources.
• Patent challenges and intellectual property disputes.
• High cash burn rate and need for additional financing.

What Are the Growth Opportunities for BCEL?

• Expansion of ATRC-101 Clinical Trials: A significant growth opportunity lies in expanding the clinical trials for ATRC-101 to include a broader range of solid tumor types and patient populations. Positive clinical data from these trials could lead to accelerated regulatory approval and commercialization, potentially capturing a significant share of the oncology market. The timeline for this growth opportunity is dependent on the successful completion of ongoing and planned clinical trials, with potential for initial data readouts within the next 1-2 years.
• Advancement of APN-122597: The development of APN-122597, a receptor tyrosine kinase inhibitor, represents another growth avenue for Atreca. Successful preclinical and clinical development of this candidate could lead to a new treatment option for patients with tumors expressing the target receptor tyrosine kinase. The market size for targeted cancer therapies is substantial, and APN-122597 could capture a portion of this market if proven effective and safe. This is likely a 3-5 year outlook.
• Commercialization of ATRC-501/MAM01 for Malaria Prevention: Atreca's collaboration with the Bill & Melinda Gates Medical Research Institute to develop ATRC-501/MAM01 for malaria prevention presents a unique growth opportunity. Successful development and commercialization of this vaccine could address a significant unmet need in global health, particularly in regions with high malaria prevalence. The timeline for this opportunity is dependent on the successful completion of clinical trials and regulatory approvals, with potential for commercialization within the next 5-7 years.
• Strategic Partnerships and Collaborations: Atreca can further expand its pipeline and capabilities through strategic partnerships and collaborations with other biotechnology and pharmaceutical companies. These collaborations can provide access to new technologies, funding, and expertise, accelerating the development and commercialization of Atreca's product candidates. The company's existing collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute demonstrate the potential of this growth strategy.
• Expansion of Discovery Platform: Atreca's proprietary discovery platform is a key differentiator and a source of future growth opportunities. By continuously investing in and expanding this platform, Atreca can identify and develop new antibody-based immunotherapeutics targeting a wider range of diseases. This platform could generate new product candidates and licensing opportunities, driving long-term growth for the company.

What Are BCEL's Competitive Advantages?

• Proprietary antibody discovery platform.
• Novel mechanism of action of ATRC-101.
• Strategic collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute.

What Does BCEL Do?

Atreca, Inc., founded in 2010 and based in San Carlos, California, is a clinical-stage biopharmaceutical company dedicated to developing antibody-based immunotherapeutics for a variety of solid tumor types. The company's core mission revolves around identifying and developing novel cancer treatments by leveraging its unique discovery platform, which allows for the isolation and characterization of antibodies directly from patients' immune responses. Atreca's lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target. Preclinical data indicates that ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients, suggesting broad potential applicability. Beyond ATRC-101, Atreca is also developing APN-122597, a receptor tyrosine kinase inhibitor targeting tumor tissues, and ATRC-501/MAM01, which targets the circumsporozoite protein of Plasmodium falciparum for the prevention of malaria. The company has established strategic collaborations to expand its research and development capabilities. A collaboration and license agreement with Xencor, Inc. focuses on the research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Additionally, Atreca has a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for malaria prevention.

What Products and Services Does BCEL Offer?

• Discovers and develops antibody-based immunotherapeutics.
• Focuses on treating a range of solid tumor types.
• Develops ATRC-101, a monoclonal antibody with a novel mechanism of action.
• Develops APN-122597, a receptor tyrosine kinase inhibitor targeting tumor tissues.
• Develops ATRC-501/MAM01 for the prevention of malaria.
• Collaborates with Xencor, Inc. for novel CD3 bispecific antibodies in oncology.
• Partners with the Bill & Melinda Gates Medical Research Institute for malaria prevention.

How Does BCEL Make Money?

• Develops and out-licenses antibody-based therapeutics.
• Generates revenue through research collaborations and licensing agreements.
• Aims to commercialize its own developed therapeutics.

What Industry Does BCEL Operate In?

Atreca operates within the highly competitive biotechnology industry, which is characterized by intense research and development, stringent regulatory requirements, and a high degree of risk. The market for cancer immunotherapies is experiencing rapid growth, driven by advances in understanding the role of the immune system in fighting cancer. Key trends include the development of personalized medicine approaches and the exploration of combination therapies. Atreca's focus on antibody-based immunotherapeutics positions it within this growing market, but the company faces competition from larger, more established players with greater resources.

Who Are BCEL's Key Customers?

• Patients with solid tumor cancers.
• Patients at risk of malaria.
• Pharmaceutical companies through licensing and collaboration agreements.

Company Profile

Atreca, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO John A. Orwin. BCEL has traded publicly since 2019.

Atreca, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -37.57 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Atreca, Inc. stands at -83.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.7%, showing how much profit it generates from its asset base. A current ratio of 4.79 indicates the company holds enough short-term assets to cover its near-term obligations.

BCEL Valuation & Market Position

With a $3.57M market cap, Atreca, Inc. sits in the micro-cap segment of the market.

Wall Street analysts project Atreca, Inc. revenue of about $303K for fiscal 2026, with EPS near $-0.75.

The most recent 12 insider filings for Atreca, Inc. break down as 11 sales and 1 purchases. On net that is roughly 441K shares disposed (about $335K), a signal worth weighing alongside the fundamentals.

BCEL Financials

BCEL Latest News

BCEL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources